MA31108B1 - Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc - Google Patents
Derives substitues de spirochromanone en tant qu'inhibiteurs d'accInfo
- Publication number
- MA31108B1 MA31108B1 MA32114A MA32114A MA31108B1 MA 31108 B1 MA31108 B1 MA 31108B1 MA 32114 A MA32114 A MA 32114A MA 32114 A MA32114 A MA 32114A MA 31108 B1 MA31108 B1 MA 31108B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- cyclo
- alkyl
- alkoxy
- optionally substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000006828 (C2-C7) alkoxycarbonyl group Chemical group 0.000 abstract 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- BNIFVTPIXGUZCU-UHFFFAOYSA-N 1h-indazole Chemical compound C1=CC=C2C=NNC2=C1.C1=CC=C2C=NNC2=C1 BNIFVTPIXGUZCU-UHFFFAOYSA-N 0.000 abstract 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 abstract 1
- FKWUPVHNVKGGSD-UHFFFAOYSA-N 1h-thieno[2,3-c]pyrazole Chemical compound C1=NNC2=C1C=CS2 FKWUPVHNVKGGSD-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005366 cycloalkylthio group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 abstract 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
Abstract
La présente invention concerne un composé de formule générale (i) : (i) dans laquelle ar1 représente un groupe formé à partir d'un cycle aromatique choisi dans un groupe comprenant un indole, un 1h-indazole, un 2h-indazole, un 1h-thiéno[2,3-c]pyrazole, un 1h-pyrazolo[3,4-b]pyridine, un benzo[b]furanne, un benzimidazole, un benzoxazole, un 1,2-benzisoxazole et un imidazo[1,2-a]pyridine ; r1 et r2 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe cyano, un groupe alkényle en c2-c6, un groupe alcoxy en c1-c6, un groupe halo-alcoxy en c1-c6, un groupe cyclo-alkyloxy en c3-c6, un groupe alcanoyle en c2-c7, un groupe halo-alcanoyle en c2-c7, un groupe alcoxycarbonyle en c2-c7, un groupe halo-alcoxycarbonyle en c2-c7, un groupe cyclo-alkyloxycarbonyle en c3-c6, un groupe aralkyloxycarbonyle, un groupe carbamoyl-alcoxy en c1-c6, un groupe carboxy-alkényle en c2-c6 ou un groupe de -q1-n(ra)-q2-rb ; un groupe alkyle en c1-c6, aryle ou hétérocyclique facultativement substitué ; ou un groupe alkyle en c1-c6 ou alkényle en c2-c6 ayant le groupe aryle ou hétérocyclique ; r3 et r4 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe nitro, un groupe cyclo-alkyle en c3-c6, un groupe carbamoyle facultativement substitué avec un groupe alkyle en c1-c6 ou cyclo-alkyle en c3-c6 ou un groupe de -n(re)rf ; un groupe alcanoyle en c2-c7, alcoxy en c1-c6, alcoxycarbonyle en c2-c7, cyclo-alkyloxycarbonyle en c3-c6, alkylsulfonyle en c1-c6, alkylthio en c1-c6, cyclo-alkyloxy en c3-c6, cyclo-alkyle en c3-c6-alcoxy en c1-c6, cyclo-alkylsulfonyle en c3-c6, cyclo-alkylthio en c3-c6 or cyclo-alkyle en c3-c6 alkylthio-c1-c6 facultativement substitué ; ou un groupe alkyle en c1-c6 facultativement substitué ; t et u représentent chacun un atome d'azote ou un groupe méthine ; et v représente un atome d'oxygène ou un atome de soufre. Le composé de l'invention est utilisable en tant qu'agent thérapeutique pour diverses maladies liées à l'acc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88030207P | 2007-01-12 | 2007-01-12 | |
| PCT/US2008/000221 WO2008088688A1 (fr) | 2007-01-12 | 2008-01-08 | Dérivés substitués de spirochromanone en tant qu'inhibiteurs d'acc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31108B1 true MA31108B1 (fr) | 2010-01-04 |
Family
ID=39297859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32114A MA31108B1 (fr) | 2007-01-12 | 2009-07-23 | Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8093389B2 (fr) |
| EP (1) | EP2111406B1 (fr) |
| JP (1) | JP5319550B2 (fr) |
| KR (1) | KR20090108022A (fr) |
| CN (1) | CN101631791B (fr) |
| AR (1) | AR064824A1 (fr) |
| AU (1) | AU2008205638B2 (fr) |
| BR (1) | BRPI0806531A2 (fr) |
| CA (1) | CA2674573C (fr) |
| CL (1) | CL2008000067A1 (fr) |
| CO (1) | CO6190611A2 (fr) |
| CR (1) | CR10944A (fr) |
| DO (1) | DOP2009000176A (fr) |
| EC (1) | ECSP099503A (fr) |
| GT (1) | GT200900194A (fr) |
| HN (1) | HN2009001276A (fr) |
| MA (1) | MA31108B1 (fr) |
| MX (1) | MX2009007502A (fr) |
| NI (1) | NI200900139A (fr) |
| NZ (1) | NZ577825A (fr) |
| PE (1) | PE20081559A1 (fr) |
| RU (1) | RU2009130736A (fr) |
| SG (1) | SG177977A1 (fr) |
| TW (1) | TW200836727A (fr) |
| UA (1) | UA103990C2 (fr) |
| WO (2) | WO2008088688A1 (fr) |
| ZA (1) | ZA200904138B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080036041A (ko) * | 2005-07-19 | 2008-04-24 | 머크 앤드 캄파니 인코포레이티드 | 아세틸 조효소 카복실라제(ａｃｃ) 억제제로서의스피로크로마논 유도체 |
| US8138197B2 (en) * | 2007-01-12 | 2012-03-20 | Msd K.K. | Spirochromanon derivatives |
| US7946800B2 (en) | 2007-04-06 | 2011-05-24 | Brooks Automation, Inc. | Substrate transport apparatus with multiple independently movable articulated arms |
| US8752449B2 (en) | 2007-05-08 | 2014-06-17 | Brooks Automation, Inc. | Substrate transport apparatus with multiple movable arms utilizing a mechanical switch mechanism |
| WO2009097995A1 (fr) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
| WO2009144554A1 (fr) * | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase |
| US8524730B2 (en) | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
| WO2010008521A1 (fr) * | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulateurs de l’acétyl-coenzyme a carboxylase et procédés d’utilisation associés |
| CA2744154A1 (fr) | 2008-11-20 | 2010-05-27 | Genentech, Inc. | Composes inhibiteurs de pi3k de type pyrazolopyridine et leurs procedes d'utilisation |
| PT2499139E (pt) * | 2009-11-10 | 2014-02-10 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| WO2011082272A2 (fr) * | 2009-12-31 | 2011-07-07 | Deka Products Limited Partnership | Ensemble pompe à perfusion |
| CA2812526A1 (fr) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Amides de chromene heterocyclique-piperidine spirocyclique utiles comme modulateurs des canaux ioniques |
| CN101851237B (zh) * | 2010-06-18 | 2012-10-17 | 南方医科大学 | 一种螺环化合物及其制备方法和应用 |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| HUE025078T2 (en) | 2010-10-29 | 2016-01-28 | Pfizer | N1 / N2-lactam-acetyl-CoA carboxylase inhibitors |
| WO2012077655A1 (fr) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Dérivé spiro présentant une activité agoniste de gpr119 |
| BR112013019211A2 (pt) | 2011-02-02 | 2021-07-06 | Vertex Pharma | amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon |
| CN103443105A (zh) | 2011-02-18 | 2013-12-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺 |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| PE20141187A1 (es) | 2011-04-22 | 2014-09-18 | Pfizer | Inhibidores sustituidos de aeitl-coa carboxilasa |
| WO2012161119A1 (fr) * | 2011-05-20 | 2012-11-29 | 興和株式会社 | Nouveau dérivé de spiropipéridine et produit pharmaceutique le contenant |
| WO2013113716A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| WO2013113773A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés fongicides de pyrimidine |
| WO2013113720A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| EP2809659A1 (fr) | 2012-02-03 | 2014-12-10 | Basf Se | Composés de pyrimidine fongicides |
| JP2015511940A (ja) | 2012-02-03 | 2015-04-23 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 殺菌性ピリミジン化合物 |
| WO2013113788A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| WO2013113776A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2970177A1 (fr) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Composés indoliques activant l'ampk |
| CN105358155A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| CA2911932A1 (fr) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et leurs utilisations |
| BR112016004118A2 (pt) | 2013-09-12 | 2017-10-17 | Pfizer | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar |
| WO2018112204A1 (fr) | 2016-12-14 | 2018-06-21 | Cephalon, Inc. | Dérivés de spiropipéridine |
| CA3068623A1 (fr) * | 2017-06-30 | 2019-01-03 | Quixgen, Inc. | Nouveaux composes spirolactones |
| CN120019059A (zh) * | 2022-07-29 | 2025-05-16 | 辉瑞公司 | 新型acc抑制剂 |
| CN119798270B (zh) * | 2025-01-06 | 2026-02-24 | 中国海洋大学 | 靶向egfr的小分子化合物及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2814983A1 (de) * | 1978-04-07 | 1979-10-18 | Bayer Ag | Neue chromanon-derivate |
| JPH03182725A (ja) | 1989-12-08 | 1991-08-08 | Internatl Business Mach Corp <Ibm> | 非線形光学素子及びその製造方法 |
| US5206240A (en) * | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| ATE169001T1 (de) | 1993-01-28 | 1998-08-15 | Merck & Co Inc | Substituierte spiro-azaringen als tachykinine rezeptor antagonisten |
| CA2189634A1 (fr) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Bibliotheque combinatoire de dihydrobenzopyranes |
| US5856083A (en) | 1994-05-06 | 1999-01-05 | Pharmacopeia, Inc. | Lawn assay for compounds that affect enzyme activity or bind to target molecules |
| US6017768A (en) | 1994-05-06 | 2000-01-25 | Pharmacopeia, Inc. | Combinatorial dihydrobenzopyran library |
| US5688997A (en) * | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
| JP2001516330A (ja) | 1995-06-06 | 2001-09-25 | メルク エンド カンパニー インコーポレーテッド | アルファ１ａアドレナリンレセプターアンタゴニスト |
| GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| GB0003397D0 (en) * | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2002020509A2 (fr) | 2000-09-06 | 2002-03-14 | Bayer Aktiengesellschaft | Medicament pour lutter contre des maladies virales |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| JP2005320250A (ja) | 2002-05-09 | 2005-11-17 | Ajinomoto Co Inc | ビスラクトン誘導体及びその医薬組成物としての使用 |
| WO2004058727A1 (fr) | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite |
| JPWO2004092179A1 (ja) * | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| US8138342B2 (en) * | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| MX2007005820A (es) | 2004-11-18 | 2007-07-18 | Incyte Corp | Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos. |
| US20090215742A1 (en) | 2005-05-03 | 2009-08-27 | Pfizer, Inc. | Amide resorcinol compounds |
| KR20080036041A (ko) | 2005-07-19 | 2008-04-24 | 머크 앤드 캄파니 인코포레이티드 | 아세틸 조효소 카복실라제(ａｃｃ) 억제제로서의스피로크로마논 유도체 |
| EP2097420B1 (fr) * | 2006-11-29 | 2012-04-04 | Pfizer Products Inc. | Spirocétone inhibiteurs de la acétyl-coa carboxylase |
| US8138197B2 (en) * | 2007-01-12 | 2012-03-20 | Msd K.K. | Spirochromanon derivatives |
-
2008
- 2008-01-04 PE PE2008000089A patent/PE20081559A1/es not_active Application Discontinuation
- 2008-01-07 TW TW097100608A patent/TW200836727A/zh unknown
- 2008-01-08 CA CA2674573A patent/CA2674573C/fr not_active Expired - Fee Related
- 2008-01-08 AU AU2008205638A patent/AU2008205638B2/en not_active Ceased
- 2008-01-08 SG SG2012002739A patent/SG177977A1/en unknown
- 2008-01-08 JP JP2009545577A patent/JP5319550B2/ja not_active Expired - Fee Related
- 2008-01-08 KR KR1020097014377A patent/KR20090108022A/ko not_active Withdrawn
- 2008-01-08 NZ NZ577825A patent/NZ577825A/en not_active IP Right Cessation
- 2008-01-08 UA UAA200908468A patent/UA103990C2/ru unknown
- 2008-01-08 WO PCT/US2008/000221 patent/WO2008088688A1/fr not_active Ceased
- 2008-01-08 CN CN2008800021443A patent/CN101631791B/zh not_active Expired - Fee Related
- 2008-01-08 MX MX2009007502A patent/MX2009007502A/es unknown
- 2008-01-08 US US12/007,000 patent/US8093389B2/en active Active
- 2008-01-08 WO PCT/US2008/000223 patent/WO2008088689A1/fr not_active Ceased
- 2008-01-08 RU RU2009130736/04A patent/RU2009130736A/ru not_active Application Discontinuation
- 2008-01-08 EP EP08713050A patent/EP2111406B1/fr active Active
- 2008-01-08 BR BRPI0806531-4A2A patent/BRPI0806531A2/pt not_active IP Right Cessation
- 2008-01-09 AR ARP080100081A patent/AR064824A1/es not_active Application Discontinuation
- 2008-01-10 CL CL200800067A patent/CL2008000067A1/es unknown
-
2009
- 2009-06-12 ZA ZA200904138A patent/ZA200904138B/xx unknown
- 2009-07-06 GT GT200900194A patent/GT200900194A/es unknown
- 2009-07-06 HN HN2009001276A patent/HN2009001276A/es unknown
- 2009-07-08 NI NI200900139A patent/NI200900139A/es unknown
- 2009-07-09 EC EC2009009503A patent/ECSP099503A/es unknown
- 2009-07-09 DO DO2009000176A patent/DOP2009000176A/es unknown
- 2009-07-13 CO CO09072490A patent/CO6190611A2/es active IP Right Grant
- 2009-07-20 CR CR10944A patent/CR10944A/es unknown
- 2009-07-23 MA MA32114A patent/MA31108B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31109B1 (fr) | Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. | |
| MX2009007502A (es) | Derivados de espirocromanona sustituidos. | |
| WO2008088692A3 (fr) | Dérivés spirochromanone | |
| Ravi et al. | N-chlorosuccinimide-promoted regioselective sulfenylation of imidazoheterocycles at room temperature | |
| Fei et al. | New substituted benzimidazole derivatives: a patent review (2010–2012) | |
| Manetti et al. | Identification of a novel pyrazolo [3, 4-d] pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice | |
| CA3015271C (fr) | Derives de dioxyde d'iminothiadiazinane utilises comme inhibiteurs de la plasmepsine v | |
| ZA200500022B (en) | 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligans | |
| JP2006517966A (ja) | ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体 | |
| CA2729690A1 (fr) | Nouveaux pyrrolo [2,3-a] carbazoles et leur utilisation comme inhibiteurs des kinases pim | |
| TW200413379A (en) | Fused azole-pyrimidine derivatives | |
| AU2018326721A1 (en) | Compounds and compositions for IRE1 inhibition | |
| EP2800569B1 (fr) | Modulateurs allostériques de récepteurs de cannabinoïdes cb1 | |
| Abdulla | Synthesis and antimicrobial activity of Ibuprofen derivatives | |
| Wang et al. | Imidazolium chloride as an additive for synthesis of 4 (3H)-quinazolinones using anthranilamides and DMF derivatives | |
| Liu et al. | Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo [1, 5-a] pyrazine core featuring 3-position bicyclic ring substitutes | |
| Zeng et al. | Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization | |
| PE20100737A1 (es) | Nuevos compuestos | |
| EP3091982A1 (fr) | Composés organiques | |
| AR036735A1 (es) | Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina | |
| Badrey et al. | An approach to polysubstituted triazipines, thiadiazoles and thiazoles based on benzopyran moiety through the utility of versatile hydrazonoyl halides as in vitro monoamine oxidase inhibitors | |
| Leca et al. | Acid-Catalyzed Aza-Diels− Alder Reactions for the Total Synthesis of (±)-Lapatin B | |
| Lotfata et al. | A Simple and Efficient Regioselective and Chemoselective Synthesis of New Substituted 3‐Methyl‐6‐arylpyridazine‐4‐carboxamides and 5‐Oxo‐3‐aryl‐5, 6‐dihydropyrido [4, 3‐c] pyridazine‐8‐carbaldehydes | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| Khidre et al. | Synthesis and Antimicrobial Activity of Novel Heterocycles Utilizing 3‐(1, 4‐Dioxo‐3, 4‐dihydrophthalazin‐2 (1 H)‐yl)‐3‐oxopropanenitrile as Precursors |